MGD 009

Drug Profile

MGD 009

Alternative Names: B7-H3 x CD3; B7-H3 x CD3 DART protein; MGD009

Latest Information Update: 29 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD276 protein inhibitors; CD3 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 26 Jan 2018 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03406949)
  • 07 Mar 2016 Pharmacokinetics and pharmacodynamics data from a preclinical studies in Solid tumours released by MacroGenics
  • 01 Sep 2015 Phase-I clinical trials in Solid tumours (Late-stage, Metastatic) in USA (IV) (NCT02628535)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top